Transparency Market Research
The global neuronal monoclonal antibodies market can be segmented based on drug class, application, distribution channel, and region. In terms of drug class, the global neuronal monoclonal antibodies market can be classified into amyloid inhibitors, tau protein inhibitors, alpha-synuclein inhibitors, integrin antagonists, and others. Based on application, the global neuronal monoclonal antibodies market can be segmented into multiple sclerosis, Parkinson’s disease, Alzheimer's disease, amyotrophic lateral sclerosis, and others. The multiple sclerosis segment is expected to hold a significant share of the market due to approval of monoclonal antibodies. In terms of distribution channel, the market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is expected to expand at a significant CAGR during forecast period, owing to an increase in the number of Internet users, availability of medicines at a low cost online compared to hospital and retail pharmacies, and ease of useof the online platform.
Based on geography, the global neuronal monoclonal antibodies market can be classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Currently, North America dominates the global neuronal monoclonal antibodies market and is closely followed by Europe. High prevalence of neurological diseases, availability of highly advanced health care facilities, strong clinical pipeline of neuronal monoclonal antibodies, higher health care spending, and availability of reimbursement policies are some of the factors boosting the neuronal monoclonal antibodies market in North American and Europe. The market in Asia Pacific is expected to exhibit a significant potential in the near future. Factors such as rapidly developing health care infrastructure, rise in disposable income, increase in the burden of Alzheimer's disease and other dementias, increasing healthcare spending, and government initiatives in the countries of Asia Pacific are some of the factors that are expected to fuel the growth of the neuronal monoclonal antibodies in Asia Pacific. India, China, and Japan are expected to exhibit significantly higher growth potential in the neuronal monoclonal antibodies market in Asia Pacific, owing to a large population base with high clinical unmet needs. The neuronal monoclonal antibodies market Middle East & Africa is estimated to expand at a steady rate during forecast period, owing to poorly developed health care facilities in the region.
Major players operating in global neuronal monoclonal antibodies market are GlaxoSmithKline, Sanofi S. A., Biogen, Eli Lilly & Co. Bristol-Myers Squibb, and many more.
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
The main aim of the report is to:
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.